CE Mark Granted for Novel Cryoablation Device Aimed at Reducing the Incidence of Esophageal Cancer

Redwood City, Calif. – October 22, 2015 – C2 Therapeutics, a privately-held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced that it received the CE (Conformité Européenne) mark for its Coldplay CryoBalloon® Focal Ablation System. The product is now available for commercial use initially in parts of Western Europe. Cryoablation is a process that uses extreme cold to precisely destroy or damage diseased tissue while minimizing damage to surrounding healthy tissue.

Click here to see full release.